The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday. Trials of the ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...

Eli Lilly and Company LLY announced that the FDA has approved its popular obesity drug, Zepbound (tirzepatide) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.

The first medication for obstructive sleep apnea has been approved by the U.S. Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly's Zepbound ...